1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAltretamineCat. No.: HY-B0181CAS No.: 645-05-6Synonyms: ENT-50852; RB-1515; WR-95704分式: CHN分量: 210.28作靶點: DNA Alkylator/Crosslinker作通路: Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶

2、解性數據體外實驗 DMSO : 8.33 mg/mL (39.61 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 0.83 mg/mL (3.95 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 0.83 mg/mL (3.95 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Altr

3、etamine種烷化劑 (alkylator)，具有抗腫瘤活性。體外研究 Altretamine is an antineoplastic agent 1.體內研究 Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearingMV522 cells 1.PROTOCOLAnimal Mice 1Administration 1 Balb/c nu/nu 4 week old female mice weighing 18-22 g,

4、receive s.c. injections of 8-10 million MV522 cells.Altretamine is administered i.p. three times a week for 3 weeks, starting on day 10 after tumor implantation.Tumor size is measured in two perpendicular diameters and tumor weight (TW) estimated according to theformula: w = (width)2 length/2. Altre

5、tamine is prepared as stock solutions of 1-10 mg/mL in 40%DMSO/normal saline and diluted with 10% DMSO/normal saline as required 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發表的科研獻 J Mol Med (Berl). 2019 Jun 14.See more customer validations on

6、 HYPERLINK / www.MedChemEREFERENCES1. Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine,alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400